Galapagos NVLatest Galapagos NV News and UpdatesCompany & Industry OverviewsAbbVie Expects to Commercialize Selective JAK1 Inhibitor ABT-494Currently being tested in six Phase 3 trials, ABT-494 is expected to be a significant improvement in the standard of care for rheumatoid arthritis.
Company & Industry OverviewsAbbVie Expects to Commercialize Selective JAK1 Inhibitor ABT-494Currently being tested in six Phase 3 trials, ABT-494 is expected to be a significant improvement in the standard of care for rheumatoid arthritis.
